Therapeutic Plasma Exchange in Septic Shock: A Pilot Study
NCT05093075
Recruiting
The investigators propose to conduct a multi-center randomized pilot feasibility trial comparing therapeutic plasma exchange to standard of care in patients diagnosed with septic shock.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/12/2025
Locations: Foothills Medical Centre, Calgary, Alberta +10 locations
Conditions: Septic Shock
Register for Updates
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257
Recruiting
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: National Heart Institute, Beverly Hills, California +23 locations
Conditions: Heart Failure
Register for Updates
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914
Recruiting
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate the effectiveness of atogepant in treating adult participants with migraine in a real-world setting. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 1000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study across the world. Partici... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Neurology and Neurodiagnostics of Alabama /ID# 267614, Hoover, Alabama +79 locations
Conditions: Migraine
Register for Updates
Brain STimulation for ANxiety and Depression in Youth
NCT06892847
Recruiting
In this open-label trial, the overall aim is to determine if TMS treatment can improve anxiety and depression in a broad group of children and youth referred by physicians.
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
08/12/2025
Locations: Alberta Children's Hospital, Calgary, Alberta
Conditions: Anxiety Disorders, Depression
Register for Updates
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
NCT04462770
Recruiting
This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/12/2025
Locations: Children's Hospital of Los Angeles, Los Angeles, California +45 locations
Conditions: Dravet Syndrome
Register for Updates
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This eve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/12/2025
Locations: University of Alabama at Birmingham- Site Number : 8401135, Birmingham, Alabama +357 locations
Conditions: Multiple Sclerosis
Register for Updates
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
NCT05568459
Recruiting
This study is focused on males who have Hemophilia B and who need regular preventive treatment with factor IX protein (FIX) replacement therapy to prevent and also to control their bleeding events. The aim of the study is to gather at least 6 months of information on bleeding events for each individual participant while they continue to use their usual FIX replacement therapy. There is no experimental treatment being tested in this study. The study is informational, and part of a larger program... Read More
Gender:
MALE
Ages:
16 years and above
Trial Updated:
08/12/2025
Locations: Orthopaedic Hemophilia Treatment Center, Los Angeles, California +21 locations
Conditions: Hemophilia B
Register for Updates
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
NCT06667414
Recruiting
For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and medication history. At the end of the visit, a blood sample will be drawn to allow testing with a sequencing assay that is specifically designed for phasing single nucleotide polymorphisms (SNPs) on the... Read More
Gender:
ALL
Ages:
Between 25 years and 60 years
Trial Updated:
08/12/2025
Locations: Uab Medicine, Birmingham, Alabama +40 locations
Conditions: Huntington Disease
Register for Updates
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
NCT06637332
Recruiting
This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Concord Repatriation and General Hospital, Concord, New South Wales +12 locations
Conditions: Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, S. Aureus Bacteremia, S. Aureus Bloodstream Infection, Staphylococcus Aureus Endocarditis
Register for Updates
A Performance Study Comparing the EyeMirage (Test Device) to Standard of Care (Reference Device) in Patients 18 to 65 Years of Age Undergoing Standard Eye Examinations Such as Visual Acuity, Visual Field, Color Vision, and Self-Paced Saccade for Various Conditions
NCT06908967
Recruiting
This study will assess the effectiveness and accuracy of results of a new device for eye function testing. This will be done by comparing results of four eye tests that are done through the current standard used in eye clinics and that of this new device. Participants of this study will undergo the four eye tests using both the new device and the standard of care devices. The study will be done in one visit to the eye clinic. Thirty days after the eye tests were done, participants will be calle... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/12/2025
Locations: St. Boniface Eye Care Centre, Winnipeg, Manitoba +3 locations
Conditions: Visual Function
Register for Updates
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
NCT06428396
Recruiting
The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) unresectable metastatic breast cancer. There is no formal hypothesis testing in this study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: City of Hope - Phoenix ( Site 0006), Goodyear, Arizona +36 locations
Conditions: Metastatic Breast Cancer
Register for Updates
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
NCT04176198
Recruiting
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: University of Alabama, Birmingham, Alabama +77 locations
Conditions: Myelofibrosis
Register for Updates